PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

Financials out for quarter ending 3/31/17
Now all up to date and current
Cash up over 1200% (While the number is small, the point is the company is paying its bills contrary to the false reports to the contrary.)
Sales of about $190K for 9 month period
$2.8 million loss carry forward which I anticipate being useful when India sales start after conclusion of the approval process, and pending release of the latest study which would potentially be huge for sales if Sucanon performs as it has in previous documented preclinical and clinical studies.
The value in ROTH is the consistent scientific efficacy of Sucanon over several documented studies.
The company remains viable awaiting
-study results vs Metformin
-pending approval in India
-ongoing sales in Mexico